Scailyte

🚀 Scailyte is thrilled to be part of the LIFE SCIENCE INDUSTRY MEETS DATA SCIENCE symposium organised by CSEM and Bio-Techne, where cutting-edge innovations are taking center stage. This event is set to redefine how data-driven solutions are revolutionizing the life science sector, from bioprocesses to biopharma and health. 👨🏫 Our Senior Data Scientist, Sukalp Muzumdar, PhD Muzumdar, will deliver on the promises of single-cell data through machine learning. 🌟 Don't miss out on this opportunity to learn how machine learning is unlocking new potentials in single-cell data and pushing the boundaries of what's possible in life sciences. 👫 Join us to explore new frontiers, network with industry leaders, and be inspired by how data science is driving the future of life sciences. See you there! 👋 https://lnkd.in/dYQSNXNa #LifeScience #DataScience #Innovation #MachineLearning #SingleCellData #Biopharma #HealthTech #Scailyte

🌇 Scailyte is thrilled to attend Hanson Wade's 14th World CB & CDx Summit - the flagship CDx event of the year in Boston, September 3-6! 💊 This premier forum is dedicated to advancing biomarker research and companion diagnostics. Gathering leading biopharma, academia, and solution providers, this meeting enables impactful conversations around the industry’s latest developments, regulatory changes, and innovative strategies. 👯 Join our CBO Tim Foley and our Principal Scientist DIana Stoycheva  next week and enjoy discussions the impact of global regulatory frameworks and the integration of AI and digital pathology advancing precision medicine. #WorldCDxSummit #CDx #CompanionDiagnostics #ClinicalBiomarkers #PrecisionMedicine #SingleCellMultiomics #AI #Innovation #BiotechConference

🌟 We’re thrilled to announce a major milestone in the field of endometriosis! Scailyte, in collaboration with the University of Bern, has unveiled groundbreaking insights using our cutting-edge AI platform, ScaiVision. 🚀 🔍 Our study analyzed 466,371 cells from 60 patients, which represents the largest single-cell dataset in endometriosis to date. Using ScaiVision, we discovered key gene expression changes and altered receptor-ligand interactions in the eutopic endometrium of women with endometriosis. These findings are the of a highly specific molecular biomarker and also highlight increased inflammation, adhesion, proliferation, cell survival, and angiogenesis across various cell types. 🎯 By uncovering novel biomarkers and disease mechanisms, we’re paving the way for improved treatments in endometriosis, and most importantly, we pioneered the development of the first generation of molecular diagnostic assays in this highly prevalent and debilitating disease. 🙌 Acknowledgments We extend our heartfelt gratitude to all co-authors, study participants, physicians, nursing staff, investors, and Innosuisse for their invaluable contributions to this groundbreaking project. 📚 Read the Full Preprint https://lnkd.in/e2tBYtaT Feel free to reach out if you’d like to learn more about ScaiVision and explore how we can partner to make further groundbreaking discoveries leveraging multi-omics data and our proprietary AI platform! #singlecell #biomarkers #AI #endometriosis #womenshealth #ScaiVision

🎊 We are very proud to announce the addition of three new members to our leadership team and BoD as we continue to grow our business and to expand our presence in North America. Tim Foley as Chief Business Officer,  Jean-Pierre Rosat General Partner at 4FOX Ventures as Executive Chair,   Darrin Crisitello, CCO at Quanterix as member of the BoD Read more: https://lnkd.in/dFe_297h #biomarkerdiscovery #precisionmedicine #singlecellomics #AI #boardofdirectors #lifesciences #drugdiscovery #biotech #dataanalysis #personalizedmedicine #scailyte #Quanterix

🔊 We never shared the efforts we put in developing our pipeline but this time we want to recognize this achievement: 💡 ScaiTrack: a tool to trace and reproduce our analyses. 🤓 While developing tools like ScaiTrack could be considered extraneous to our primary goal of discovering biomarkers from single-cell data, we believe that this work is integral to ensuring the quality of what we deliver to our partners. It reflects how we live one of Scailyte’s core company values: Passion for quality that matters. With ever-more-complex AI tools and methods constantly being released, reproducibility and traceability have become more important than ever as a cornerstone of credible and reliable data analysis. Not only does reproducibility allow for an independent verification of results and detection of potential errors or biases, it promotes transparency in scientific research, building trust within the community. At Scailyte, we’ve taken steps in the past to improve reproducibility in our algorithms and machine learning models, such as fixing a seed to ensure deterministic behavior. However, this could be considered “low-hanging fruit”, because as much as we would like to avoid it, irreproducibility often arises due to human actions during the course of a data analysis project - the small things that a data scientist does slightly differently from one analysis to another. We built a tool to help us track our analysis process, which we call ScaiTrack.  When a data scientist activates ScaiTrack, it records all of the commands that he or she runs on the command line along with all outputs and the time at which commands were issued. Moreover, it can filter out commands like *ls* and *cd* which don’t modify the content or structure of any files on the system, keeping only the “important” commands for easy lookup. On top of that, it allows our data scientists to log the complete list of packages installed, monitor any changes that occur to specified files, and detail the differences made after file editing with a text editor like vim. With this tool, we can easily trace back all of the actions we’ve taken in order to ensure traceability and reproducibility of our results.  Our robust Quality Management System (compliant with ISO9001 and key regulations of HIPAA, GDPR, GCP, GLP), as well as very comprehensive data protection and cybersecurity policies and infrastructure, underscore our dedication to deliver robust and reproducible results in compliance with industry standards and handle sensitive patient data with utmost care. 📬 Reach out to us if you want to learn more about ScaiVision and how we can partner! contact@scailyte.com

💡 Innovation meets industry: we are looking forward to exciting talks and intense discussions at the Single-Cell & Spatial Day in Basel organized by 10x Genomics and Novartis. 📣 Our own senior data scientist Shaoline S. will present our unique discovery approach. #AI, #singlecell, #precisionmedicine, #biomarkers

We are so proud to welcome Virginia Savova, Ph. D. as a Strategic and Scientific Advisor! Her experience and passion for innovation and cutting-edge technologies and her vision for biomarker-driven drug discovery is one more validation for our mission! More here: https://lnkd.in/d7sjBhA5 #AI, #biomarkerdiscovery, #precisionmedicine, #immunology, #singlecell

🔍 Unveiling Insights into T cell subsets in ICI-associated adverse events: Exploring the Latest Research in Single-Cell Technologies! 🧬 We're thrilled to share the latest instalment of our ScaiDigest series! In this volume, we delve into two recent articles using single-cell transcriptomic data to analyse the contribution of different imune cell subsets to ICI-induced colitis. Sukalp is thrilled to provide a summary & his perspective of these two papers for our ScaiDigest. 💡 Don't miss out on these highlights! Dive into Sukalp's commentary on the complex biology of ICIs using multiomic approach! #ScaiDigest , #SingleCellTechnologies #Innovation #Healthcare  #singlecell #biomarkers #oncology #immunotherapy

Last week I was at the #BIO2024 exploring partnership opportunities with biotech & pharma companies from around the world. This was a very well organized, vibrant & colorful event in the emerging biotech hub San Diego. Some key insights: - biomarker-driven drug discovery and companion diagnostics is gaining importance outside of oncology, in particular in auto-immunity; - there is a new wave of immuno-oncology drugs, which are showing very promising results with overall response rates of >80% and complete response in >40% of patients in early clinical trials. - genAI and large language models are a hype also in the biotech space - a lot of talk with no results or solid science to back up the claims of these new genAI companies - the bubble gets inflated.